Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Morris

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Clinical Pharmacology in Drug Development|July 14, 2023
Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor ItraconazoleClaire Miller, Roberto Sommavilla, Simon T Barry, et al.
Human Pathology|August 2, 2011
Ectomesenchymoma with t(1;12)(p32;p13) evolving from embryonal rhabdomyosarcoma shows no rearrangement of ETV6Sinead Howley, Deirdre Stack, Thomas Morris, et al.
BMC Public Health|October 13, 2011
Who pays and who benefits? How different models of shared responsibilities between formal and informal carers influence projections of costs of dementia managementVictor Vickland, Joel Werner, Thomas Morris, et al.
BJU International|January 25, 2006
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerDavid G McLeod, Peter Iversen, William A See, et al.
BJU International|June 15, 2006
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castrationChris J Tyrrell, Peter Iversen, Teuvo Tammela, et al.
Health & Social Care in the Community|September 7, 2022
Australian residential aged care home staff experiences of implementing an intervention to improve palliative and end-of-life care for residents: A qualitative studySrivalli Vilapakkam Nagarajan, Christopher J Poulos, Josephine M Clayton, et al.
Journal of Public Health Management and Practice : JPHMP|December 11, 2013
Conceptualizing and measuring community preparedness within public health preparedness and response: complexities and lessons learnedKaren E Kun, Dale A Rose, Thomas Morris, et al.
Drugs & Aging|January 21, 2025
Psychotropic Polypharmacy in Dementia: A Retrospective Analysis for People with Neuropsychiatric Symptoms Referred to an Australian Dementia Support ServiceMustafa Atee, Andrew Stafford, Daniel Whiting, et al.
European Urology|February 3, 2007
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response studyYves Fradet, Blair Egerdie, Morten Andersen, et al.
Clinical Genitourinary Cancer|December 26, 2022
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate CancerNeal Shore, Begoña Mellado, Satish Shah, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Clinical Pharmacology in Drug Development|July 14, 2023
Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor ItraconazoleClaire Miller, Roberto Sommavilla, Simon T Barry, et al.
Human Pathology|August 2, 2011
Ectomesenchymoma with t(1;12)(p32;p13) evolving from embryonal rhabdomyosarcoma shows no rearrangement of ETV6Sinead Howley, Deirdre Stack, Thomas Morris, et al.
BMC Public Health|October 13, 2011
Who pays and who benefits? How different models of shared responsibilities between formal and informal carers influence projections of costs of dementia managementVictor Vickland, Joel Werner, Thomas Morris, et al.
BJU International|January 25, 2006
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerDavid G McLeod, Peter Iversen, William A See, et al.
BJU International|June 15, 2006
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castrationChris J Tyrrell, Peter Iversen, Teuvo Tammela, et al.
Health & Social Care in the Community|September 7, 2022
Australian residential aged care home staff experiences of implementing an intervention to improve palliative and end-of-life care for residents: A qualitative studySrivalli Vilapakkam Nagarajan, Christopher J Poulos, Josephine M Clayton, et al.
Journal of Public Health Management and Practice : JPHMP|December 11, 2013
Conceptualizing and measuring community preparedness within public health preparedness and response: complexities and lessons learnedKaren E Kun, Dale A Rose, Thomas Morris, et al.
Drugs & Aging|January 21, 2025
Psychotropic Polypharmacy in Dementia: A Retrospective Analysis for People with Neuropsychiatric Symptoms Referred to an Australian Dementia Support ServiceMustafa Atee, Andrew Stafford, Daniel Whiting, et al.
European Urology|February 3, 2007
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response studyYves Fradet, Blair Egerdie, Morten Andersen, et al.
Clinical Genitourinary Cancer|December 26, 2022
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate CancerNeal Shore, Begoña Mellado, Satish Shah, et al.
Pageof 9